Healthcare [ 12/13 ] | Diagnostics & Research [ 56/164 ]
NASDAQ | Common Stock
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally.
The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection.
In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment.
The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research.
The company was incorporated in 2011 and is headquartered in Palo Alto, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 29, 24 | -0.94 Increased by +27.69% | -0.85 Decreased by -10.59% |
| Feb 22, 24 | -0.85 Increased by +37.50% | -0.86 Increased by +1.16% |
| Nov 6, 23 | -0.73 Increased by +48.23% | -0.95 Increased by +23.16% |
| Aug 3, 23 | -0.67 Increased by +47.24% | -1.18 Increased by +43.22% |
| May 9, 23 | -1.30 Decreased by -7.44% | -1.32 Increased by +1.52% |
| Feb 23, 23 | -1.36 Decreased by -52.81% | -1.37 Increased by +0.73% |
| Nov 3, 22 | -1.41 Decreased by -33.02% | -1.26 Decreased by -11.90% |
| Aug 4, 22 | -1.27 Decreased by -32.29% | -1.21 Decreased by -4.96% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 168.49 M Increased by +30.90% | -114.98 M Increased by +13.89% | Decreased by -68.24% Increased by +34.22% |
| Dec 31, 23 | 155.05 M Increased by +22.19% | -187.04 M Decreased by -33.67% | Decreased by -120.63% Decreased by -9.39% |
| Sep 30, 23 | 143.03 M Increased by +21.83% | -86.10 M Increased by +46.85% | Decreased by -60.20% Increased by +56.37% |
| Jun 30, 23 | 137.15 M Increased by +25.66% | -72.77 M Increased by +68.28% | Decreased by -53.06% Increased by +74.76% |
| Mar 31, 23 | 128.71 M Increased by +33.94% | -133.53 M Decreased by -8.36% | Decreased by -103.74% Increased by +19.10% |
| Dec 31, 22 | 126.89 M Increased by +17.37% | -139.93 M Decreased by -53.92% | Decreased by -110.28% Decreased by -31.14% |
| Sep 30, 22 | 117.40 M Increased by +23.87% | -161.99 M Decreased by -50.66% | Decreased by -137.98% Decreased by -21.62% |
| Jun 30, 22 | 109.14 M Increased by +18.50% | -229.43 M Decreased by -135.13% | Decreased by -210.21% Decreased by -98.42% |